Expiration Date: February 28, 2017
Media: Internet - based
Community Practice Connections™: 10th Annual New York Lung Cancer Symposium® consists of a series of interactive clinical vignettes, short video interviews of leading lung cancer experts, and brief summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes as well as questions commonly faced in the community oncology practice setting.
CME Activity Table of Contents
- EGFR Mutation-Positive NSCLC: Frontline, Acquired Resistance, and Subsequent Therapy
- ALK-Rearranged NSCLC: Testing, Acquired Resistance, and Subsequent Therapy
- Squamous NSCLC: Frontline and Subsequent Therapy
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
- Explain how to personalize treatment strategies for patients with advanced forms of lung cancer, based on individual tumor characteristics
- Discuss current and emerging immuno-oncology strategies in the context of clinical trial findings and patient selection in advanced forms of lung cancer
- Describe current and emerging roles for agents that target the VEGF axis in advanced non–small cell lung cancer (NSCLC)
- Delineate best practices concerning the application of targeted therapies in the frontline and subsequent settings of advanced lung cancer
- Discuss evolving strategies to manage patients with acquired tyrosine kinase inhibitor resistance in advanced NSCLC
- Detail current and emerging clinical roles for anaplastic lymphoma receptor inhibition in the management of advanced NSCLC
- Explain the current role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer
- Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Faculty, Staff, and Planners' Disclosures
Chandra P. Belani, MD
Miriam Beckner Distinguished Professor of Medicine
Penn State Hershey Cancer Institute
Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: Puma Biotechnology, Pfizer, Genentech; Consultant: AstraZeneca, ARIAD Pharmaceuticals, Roche/Genentech, Array
Geoffrey R. Oxnard, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Disclosures: Consultant: AstraZeneca, Clovis Oncology, ARIAD Pharmaceuticals, Sysmex; Other: Chugai Pharma (honoraria)
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise